AIM ImmunoTech Inc. released an investor video presentation and press release on June 4, 2026, detailing previously published pre-clinical data on its lead drug candidate, Ampligen® (rintatolimod), as a potential prophylactic and/or early-onset treatment for Ebola virus disease (EVD). The company is highlighting the drug's potential in response to the ongoing Bundibugyo Ebola outbreak, which lacks approved targeted therapies or vaccines.
Key Details
- Pre-clinical Data: The company reiterated findings from a Biosafety Level 4 pre-clinical study that demonstrated 100% protective survival in a lethal Ebola mouse model when Ampligen was administered early.
- Unmet Need: The presentation focuses on the current Bundibugyo (BDBV) Ebola strain outbreak and the absence of specifically approved treatments, positioning Ampligen as a potential broad-spectrum antiviral solution.
- Regulatory Status: Ampligen has already received orphan drug designation for the treatment of Ebola virus disease from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).